COMMUNIQUÉS West-GlobeNewswire

Spectral AI Announces 2026 First Quarter Financial Results
12/05/2026
Development Work for DeepView ® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA Reiterates Annual Revenues Guidance DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. ( [...]
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
12/05/2026
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug [...]
Lumexa Imaging Announces First Quarter 2026 Results
12/05/2026
RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced results for the first quarter ended March 31, 2026, [...]
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
12/05/2026
Q1 Revenue of $9.0 million Q1 Income from Continuing Operations of $0.8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE [...]
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates
12/05/2026
Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital operating room system [...]
Nyxoah Reports First Quarter 2026 Financial and Operating Results
12/05/2026
REGULATED INFORMATION Nyxoah Reports First Quarter 2026 Financial and Operating Results Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth Continued clarity around HGNS and Genio [...]
TELA Bio Reports First Quarter 2026 Financial Results
12/05/2026
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
Jushi Holdings Inc. Reports First Quarter 2026 Financial Results
12/05/2026
Revenue of $66.4 million , Up 4% Year-over-Year, Driven by Strong Wholesale Growth and Benefits from Retail Expansion Gross Profit Margin Expanded 460 bps Year-Over-Year to 45.0% , Reflecting Improved Operational [...]
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
12/05/2026
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to [...]
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
12/05/2026
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of [...]
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE [...]
Biomea Fusion to Participate at Upcoming Investor Conferences
12/05/2026
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management will participate in [...]
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
12/05/2026
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms [...]
Lifecore Biomedical to Participate at CDMO Live Europe
12/05/2026
CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
12/05/2026
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for topline 6-month [...]
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102 in [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/05/2026
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into [...]

Pages